Mircera Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Mircera market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historic period can be attributed to several key factors. These include the rising prevalence of cancer, particularly among elderly populations, increased demand for long-acting erythropoiesis-stimulating agents (ESAs) to manage anemia, regulatory approvals for Mircera across various regions, and improved accessibility. Furthermore, greater awareness of treatment options for anemia related to chronic kidney disease (CKD) and cancer, along with continuous improvements in drug formulations, have significantly contributed to growth, particularly in patient adherence.

The growth is driven by the anticipated rise in the global cancer burden, particularly in developing regions, and increased healthcare expenditure in emerging markets. The demand for innovative anemia treatments is expected to rise, with greater adoption of Mircera in both hospital and outpatient settings. Major trends during the forecast period include the growing preference for long-acting ESAs, technological advancements, developments in healthcare infrastructure, wider adoption of Mircera in CKD management, and a heightened focus on patient-centric drug delivery systems.

The rising prevalence of chronic kidney disease (CKD) is expected to propel the growth of the mircera market going forward. CKD is a health concern characterized by the gradual loss of kidney function, often associated with conditions such as diabetes and hypertension. The increasing incidence of CKD is driven by factors such as aging populations, lifestyle changes, and improved diagnostic practices. Anemia, a common complication of CKD caused by reduced erythropoietin production, necessitates the use of erythropoiesis-stimulating agents like Mircera to manage and stabilize hemoglobin levels. For instance, in June 2023, according to Kidney Research UK, approximately 7.2 million people in the UK are living with CKD, and by 2033, the number is expected to rise to 7.61 million. Therefore, the rising prevalence of CKD drives the growth of the mircera market.

A key trend in the mircera market is focusing on developing approved solutions, particularly for pediatric patients, for the treatment of anemia associated with CKD. Pediatric patients with anemia due to CKD can benefit from Mircera (methoxy polyethylene glycol-epoetin beta), a long-acting erythropoiesis-stimulating agent that helps stimulate red blood cell production. This reduces the need for frequent injections, minimizes the risk of blood transfusions, and improves hemoglobin levels, enhancing overall growth and quality of life. For instance, in April 2024, Vifor Pharma received FDA approval to include pediatric patients aged 3 months to 17 years for Mircera's use in treating CKD-related anemia. This approval applies to both dialysis and non-dialysis patients, especially those transitioning from another ESA.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma, the developer of Mircera. This acquisition aims to expand CSL’s presence in the nephrology space and enhance its portfolio of treatments for anemia in CKD patients.

The key players operating in the mircera market is Roche.

North America was the largest region in the mircera market in 2024. The regions covered in mircera report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mircera market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Mircera is a medication designed to treat anemia associated with chronic kidney disease (CKD) and anemia in cancer patients. As a long-acting erythropoiesis-stimulating agent (ESA), it works by stimulating red blood cell production to maintain healthy hemoglobin levels. Its extended dosing schedule, typically requiring injections once every two to four weeks, makes it convenient for patients.

The main formulation types of mircera include injectable solutions and pre-filled syringes. These formulations are used to treat anemia resulting from chronic kidney disease and cancer-related anemia. Mircera is distributed through hospitals, dialysis centers, specialty clinics, and retail pharmacies. The medication serves various end-users, including adult and geriatric patients.

The mircera market research report is one of a series of new reports that provides mircera market statistics, including mircera industry global market size, regional shares, competitors with a mircera market share, detailed mircera market segments, market trends and opportunities, and any further data you may need to thrive in the mircera industry. This mircera market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mircera market consists of sales of solutions and pre-filled syringes designed to treat anemia caused by chronic kidney disease (CKD). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.